Innoviva, Inc.

US$19.10As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:INVAHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 6.36%
Div yield —
ROE 18.02%
Biotechnology
Beta (5Y) 0.37
PE TTM 7.510
TSR TTM 4.95%
Mkt cap US$1.358B
ROIC 16.04%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$18
(3.18%)
(90.57%)
Hold 0|1|2|2|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.29
0.31
0.33
0.31
4.48%
12.06%
17.94%
3.99%
Revenue$M
77.21
75.55
73.61
73.89
13.90%
9.89%
4.79%
1.32%
Peers (US$1.358B)
Cap (US$)
PE
1.389B
6.637x
Capital
TTM
5Y
10Y
Leveragex
1.761
(0.151)
(0.138)
EBIT/Intx
0.225
2.656
2.586
Own earn%
(6.56)
26.11
28.81
Sh yield%
33.64
5.64
11.48
Owners
Insiders/Inst%
1.30
51.38
Short interest%
0.55
SBC / revenue%
4.33
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
18
Op margin range%
6–11
$1 testx
0.0
Incr. ROIC%
6